Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.

This study reports that finasteride can effectively treat androgenic alopecia and may reduce prostate cancer risk by 25% in men with risk factors.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

This case report from the authors highlights a rare diagnosis of high-grade prostate cancer in a 35-year-old man, showing strong functional recovery and no detectable PSA one year after robotic-assisted radical prostatectomy despite the usual onset being significantly later in life.

This review examines the use of selenium and vitamin E supplements for reducing prostate cancer risk, finding mixed evidence that suggests benefits may be limited to individuals with specific risk factors, like low baseline levels or smoking history, rather than broadly applicable.

This study observed that men with frontal and moderate vertex baldness between ages 40 and 50 had a higher risk of aggressive prostate cancer, suggesting a potential link between baldness pattern and cancer risk.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

This study found that men who began balding at age 20 were twice as likely to develop prostate cancer later in life compared to those who did not experience early hair loss.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This study found that early-onset androgenic alopecia is associated with a higher risk of developing prostate cancer, although it was not linked to earlier diagnosis or more aggressive tumors.

This review concludes that although observational studies suggest a potential inverse association between selenium exposure and cancer risk, randomized trials show no convincing evidence that selenium supplements prevent cancer in humans and may indicate harmful effects.

This study developed a physician-guided algorithm to manage cutaneous adverse events from hormonal therapy in cancer patients, aiming to reduce treatment interruptions and enhance quality of life.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This study highlights that improved diagnostic techniques for prostate cancer could decrease the number of men needing diagnosis and treatment to save one life and identifies avoidable risk factors, such as smoking, diet, and occupation, that may influence prostate cancer risk.

This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.

Finasteride may help prevent prostate cancer.

This review highlights that several clinical and epidemiological studies link a diet high in terpenoid compounds with a decreased risk of prostate cancer, supporting the potential use of terpenoids as therapeutic ingredients in treating this disease.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This review discusses the potential benefits and risks of selenium in cancer prevention and treatment, emphasizing that while selenium may offer advantages for tumor patients, further research is needed due to mixed findings regarding diabetes risk.

This review discusses the role of vitamins, micronutrients, and diets in prostate cancer prevention and reports no new clinical results, emphasizing a shift towards focusing on diet over supplements.

Finasteride may help reduce prostate cancer risk.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review discusses the preventive use of finasteride for prostate cancer and highlights the unresolved safety concerns and potential over-diagnosis associated with its widespread recommendation.

This study found that ACE2 and TMPRSS2 genes were more highly expressed in tumors of elderly male cancer patients compared to healthy individuals, with notable differences across age and gender.

This study provides evidence supporting the feasibility of presurgical, window-of-opportunity models to evaluate the preventive potential of candidate agents in cancer, using cases from breast, prostate, and colorectal settings.

This study found that non-adherence to medication in the Prostate Cancer Prevention Trial was associated with increased all-cause mortality unrelated to prostate cancer.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

This study suggests that simple absolute threshold monitoring rules for compliance using the biomarker DHT perform similarly to more complex methods in the Prostate Cancer Prevention Trial.

Finasteride may reduce prostate cancer risk.